Roche Holding AG (CH:ROP)
:ROP
Want to see CH:ROP full AI Analyst Report?
ROP Stock Chart & Stats
CHF320.00
-CHF4.20(-1.39%)
At close: 4:00 PM EST
CHF320.00
-CHF4.20(-1.39%)
Day’s Range― - ―
52-Week RangeCHF243.90 - CHF374.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.25M
Market Cap
CHF254.20B
Enterprise ValueCHF278.62B
Total Cash (Recent Filing)CHF15.48B
Total Debt (Recent Filing)CHF31.64B
Price to Earnings (P/E)20.3
Beta1.25
Next Earnings
Jul 23, 2026EPS Estimate
9.99Next Dividend Ex-DateN/A
Dividend Yield2.94%
Share Statistics
EPS (TTM)8.38
Shares Outstanding702,562,700
10 Day Avg. Volume1,308,571
30 Day Avg. Volume1,251,256
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.73
Price to Sales (P/S)4.25
P/FCF Ratio18.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF349.55Price Target Upside9.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)20.2
Revenue Forecast (FY)CHF62.69B
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyFenebrutinib demonstrated roughly half the relapse rate versus the comparator and showed consistent reductions in brain lesions and progression measures, indicating meaningful clinical benefit.
Label Expansion PotentialA label that permits switching from aromatase inhibitor monotherapy could substantially expand the giredestrant-eligible population, and additional switch data could support such an indication.
Market Opportunity In Breast CancerGiredestrant targets the majority of hormone receptor–positive, HER2‑negative breast cancer patients and appears better tolerated than standard therapy, creating potential for broad adjuvant uptake.
Bears Say
Hepatic Safety RiskElevated liver enzymes and cases meeting biochemical Hy's law in another trial point to potential hepatotoxicity that may require additional monitoring or restrictive labeling.
Mortality Safety SignalA higher count of fatal cases in the fenebrutinib arm compared with the comparator represents a serious safety signal that could limit regulatory approval and clinician adoption.
Regulatory And Evidence HurdlesSafety concerns combined with the need for definitive randomized studies for combination regimens create regulatory and reimbursement risks that could delay broader use.
Roche Holding AG News
ROP FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was CHF243.90 and its highest was CHF374.90 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is CHF254.20B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jul 23, 2026 which is in 80 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jan 29, 2026. The company reported CHF8.375 earnings per share for the quarter, missing the consensus estimate of CHF8.515 by -CHF0.14.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Undervalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of CHF9.7 which represents an annual dividend yield of 2.94%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 9.99.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of CHF8.375 in its last earnings report, missing expectations of CHF8.515. Following the earnings report the stock price went up 2.572%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in CH:ROP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. It has a research collaboration agreement with Synlogic, Inc. for the discovery of a novel synthetic biotic for the treatment of inflammatory bowel disease (IBD). The company was founded in 1896 and is headquartered in Basel, Switzerland.
ROP Company Deck
ROP Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted strong operational execution: group sales +7% (Pharma +9%), core operating profit +13% and meaningful pipeline momentum with multiple positive Phase III readouts, approvals, a record 10 NMEs entering Phase III and launches (AXELIOS sequencing, mass spec, dengue test). Roche also secured a major U.S. government agreement and committed large U.S. investments. Material headwinds were acknowledged — notably Diagnostics headwinds from China pricing reforms (CHF 579m impact), FX and cash-flow/working capital pressures, higher taxes reducing EPS momentum, LOE effects (~CHF 700m) and safety/regulatory scrutiny (fenebrutinib liver signal). Management provided 2026 guidance (mid-single-digit sales growth, high single-digit Core EPS growth) and expects Diagnostics headwinds to diminish in 2026 and largely disappear by 2027. Overall, the positives from sales, margin expansion, prolific pipeline and strategic investments substantially outweighed the operational and market challenges discussed.View all CH:ROP earnings summariesROP Stock 12 Month Forecast
Average Price Target
CHF349.55
▲(9.23% Upside)
Technical Analysis
Options Prices
Currently, No data available
---